Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors

CONCLUSION: The combination of sapanisertib and ziv-aflibercept was generally tolerable and demonstrated anti-tumor activity in heavily pre-treated patients with advanced malignancies.PMID:38400671 | DOI:10.1002/cam4.6877

Source: Cancer Control - February 24, 2024 Category: Cancer & Oncology Authors: Niamh Coleman Bettzy Stephen Siqing Fu Daniel Karp Vivek Subbiah Jordi Rodon Ahnert Sarina A Piha-Paul John Wright Senait N Fessahaye Fengying Ouyang Bulent Yilmaz Funda Meric-Bernstam Aung Naing Source Type: research